Tafamidis (Vyndaqel, Pfizer Inc., New York, NY, USA) is the only TTR tetramer stabilizer approved for use in patients with TTR polyneuropathy [18] and in patients with transthyretin amyloid cardiomyopathy [19,20]. Here, TTR is linked to cardiac amyloidosis.